Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) stocks have downed by 58.5% and according to close sources this is a heaver blow on it trading due to the fact that recently, the company failed to show that the cannabidiol gel could work as far as the intended purposes were concerned. According to Paul Matteis, who is the Leerink Partners analyst, the fail trial was basically a clinical trial for Zynerba Pharmaceuticals Incorporation cannabidiol gel. The test was aimed at determining whether the gel could manage or even cure epilepsy in adults. This is the reason why the company’s stocks plunged down by 58.5%. This was a heavy blow as far as the stock trade was concerned.
GW Pharma Benefits from the Stock Downfall by Zynerba Pharmaceuticals
According to both internal and external business analysts, the rival GW Pharma which is based in the U.K has experienced an improvement in terms of stock value (+0.13%). Considering that this company is one of the largest companies tasked with developing cannabinoid medication, the misfortunes of Zynerba has saw GW Pharma to improve as much as 2.9% by the beginning of the week’s trading session.
Even with the Misfortunes of Zynerba Pharma, GW Pharma has underperformed
Generally, according to different business analysis from different sources, GW Pharmaceuticals has underperformed at some point in 2017. According to analysts, Matteis, this could be attributed to lack of clear positive catalysts in the backdrop of multiple competitive readouts. “We therefore believe that the failure of the ZYNE study reinforces much of one overhang on the stock and fundamentally it reinforces our view that barriers to entry for a follow CBD products are high”, said the analyst.
The other possible reason why Zynerba Pharma could still survive in its line of production after such a decline is the fact that companies developing cannabidiol therapies need government approval to claim medical benefits. In that case, outsider companies such as GW Pharma could be in a risky position of not being approved to handle cannabidiol drugs market in the U.S. GW might be in the right track of establishing itself from the misfortunes of Zynerba Pharma especially after it recorded positive results for Epidiolex in Dravet Syndrome.
Zynerba Pharmaceutical closed yesterday’s stock trade session at $6.24 after declining $0.18 or 2.80%.
